Takeda and GammaDelta Therapeutics to create new immunotherapies

Takeda has announced a new drug development collaboration with GammaDelta Therapeutics that aims to create new immunotherapies.

The research will focus on GammaDelta's novel T cell platform, which is based on the unique properties of gamma delta T cells, a conserved population of lymphocytes that contribute to many types of immune responses and immunopathology.

The aim will be to use this novel platform to discover and develop immunotherapies that can be used to treat a broad range of cancers, including solid tumours, as well as autoinflammatory diseases.

Takeda and GammaDelta Therapeutics' parent company Abingworth will commit up to $100 million (77.2 million pounds) in funding to accelerate the research, with this total to include an equity investment, an option fee and research and development funding.

Under the terms of the agreement, Takeda will appoint a director to GammaDelta Therapeutics' board and will receive an exclusive right to purchase the company.

Dr Daniel Curran, head of the centre for external innovation at Takeda, said: "This collaboration is another example of our strategy to invest in highly innovative areas of science, and we're pleased to collaborate with the experienced team at GammaDelta Therapeutics."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.